ArticleMalaria journal2025
Genetic polymorphism of circumsporozoite protein of Plasmodium falciparum isolates in children in Brazzaville, Republic of Congo.
Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe first WHO-approved malaria vaccines (RTS, S/AS01, and R21/Matrix M) target part of the Plasmodium falciparum circumsporozoite protein (PfCSP), displays a degree of polymorphism that may raise concerns about vaccine efficacy. As a prelude to vaccine implementation, the study here reports investigation on Pfcsp gene polymorphisms in isolates from Congolese individuals in the Republic of Congo.
methodsBlood samples were collected from 202 children infected with P. falciparum during a cross-sectional study from March to October 2021. The full-length Pfcsp gene was amplified by nested PCR and sequenced using the Oxford Nanopore platform.
resultsOverall, 30 haplotypes were identified in the N-terminal region of the protein. The A98G mutation was the most frequent (25.6%), while KLKQP was the most conserved motif. In the central repeat region, 50 haplotypes were found, with a predominance of the NANP motif, although some haplotypes contained the NVDP, NEDP and NVNP variants. C-terminal region was highly polymorphic, with 76 haplotypes identified among the 174 sequenced samples. In the C-terminal Th2R region, the major mutations identified included K317E (87.4%) and N321K (83.9%), with a nucleotide diversity of π = 0.16. In the Th3R region, the E357Q (75.9%) mutation was predominant, with a nucleotide diversity of π = 0.08. Neutrality tests revealed contrasting patterns of evolution between the Th2R and Th3R regions.
conclusionThis study provides baseline data on Pfcsp genetic diversity in a defined area of the Republic of Congo. The results highlight the degree of variation in natural parasite populations at gene loci relevant to vaccine-targeted epitopes of (PfCSP) antigen. Further research incorporating immunological data will be needed to conduct in-depth assessments of vaccine efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.